Rybarczyk Joanna, Kieckens Evelien, De Zutter Lieven, Remon Jean Paul, Vanrompay Daisy, Cox Eric
Laboratory of Immunology, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
Department of Veterinary Public Health and Food Safety, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
Vet Microbiol. 2017 Apr;202:38-46. doi: 10.1016/j.vetmic.2015.12.013. Epub 2015 Dec 29.
The terminal rectal mucosa has been identified as the predominant colonization site of Escherichia coli O157:H7 in cattle, thus a possible intervention approach should directly target this colonization site. To determine the effect of lactoferrin on E. coli O157:H7 mucosal colonization at the rectum, five 6-month-old Holstein-Friesian calves were experimentally infected with E. coli O157:H7 and received daily rectal treatment with bovine lactoferrin. Three calves that did not receive the lactoferrin served as control group. The treatment decreased faecal shedding of E. coli O157:H7 and completely eliminated the infection in all animals (n=5) after 19 days administration. The rectal mucosa of all animals (n=5) was cleared from E. coli O157:H7 within 13 days of lactoferrin treatment. To evaluate the local immune responses, three calves treated previously with lactoferrin and three calves of the control group were re-infected when E. coli O157:H7 excretion was no longer detected. The rectal administration of lactoferrin resulted in an EspA- and EspB-specific IgA responses at the rectal mucosa. These mucosal antibodies were not detected in the animals which did not receive the lactoferrin powder. Interestingly, no serum IgA antibodies could be found in animals of the group that received the lactoferrin. These findings emphasize the ability of bovine lactoferrin to clear E. coli O157:H7 colonization in cattle, where lactoferrin may influence the local immune processes against E. coli O157:H7 infection. Thus, bovine lactoferrin treatment could be used in the field to eliminate high-level faecal excretion of E. coli O157:H7 in cattle.
直肠末端黏膜已被确定为牛体内大肠杆菌O157:H7的主要定植部位,因此一种可能的干预方法应直接针对该定植部位。为了确定乳铁蛋白对大肠杆菌O157:H7在直肠黏膜定植的影响,五头6月龄的荷斯坦-弗里生犊牛被实验性感染大肠杆菌O157:H7,并每天接受牛乳铁蛋白的直肠治疗。三头未接受乳铁蛋白的犊牛作为对照组。治疗降低了大肠杆菌O157:H7的粪便排出量,并在给药19天后完全消除了所有动物(n = 5)的感染。在乳铁蛋白治疗的13天内,所有动物(n = 5)的直肠黏膜中的大肠杆菌O157:H7均被清除。为了评估局部免疫反应,当不再检测到大肠杆菌O157:H7排泄时,对三头先前用乳铁蛋白治疗的犊牛和三头对照组犊牛进行再次感染。直肠给予乳铁蛋白导致直肠黏膜产生EspA和EspB特异性IgA反应。在未接受乳铁蛋白粉的动物中未检测到这些黏膜抗体。有趣的是,在接受乳铁蛋白的组的动物中未发现血清IgA抗体。这些发现强调了牛乳铁蛋白清除牛体内大肠杆菌O157:H7定植的能力,其中乳铁蛋白可能影响针对大肠杆菌O157:H7感染的局部免疫过程。因此,牛乳铁蛋白治疗可用于在现场消除牛体内大肠杆菌O157:H7的高水平粪便排泄。